AstraZeneca inks simpler deal for nirsevimab in US
11th Apr 2023 07:51
(Sharecast News) - AstraZeneca, Swedish Orphan Biovitrum (Sobi) and Sanofi have simplified their contractual arrangements for the development and commercialization of nirsevimab in the US, they announced on Tuesday.
Read moreAstraZeneca reports positive analysis from ovarian cancer trial
5th Apr 2023 07:49
(Sharecast News) - AstraZeneca announced positive high-level results from analysis of an ongoing ovarian cancer treatment trial on Wednesday.
Read moreAstraZeneca drug recommended for EU marketing authorisation
3rd Apr 2023 07:49
(Sharecast News) - An AstraZeneca treatment for a rare autoimmune disease has been given a potential green light by the European Union, the drugs giant said on Monday.
Read moreAstraZeneca's Imfinzi trial shows 'significantly improved' event-free survival rates
9th Mar 2023 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Thursday that results from a phase III trial on its resectable non-small cell lung cancer treatment had shown a "significantly improved" event-free survival.
Read moreAstraZeneca, Daiichi's Enhertu hits trial targets
6th Mar 2023 07:14
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has met prespecified targets in a phase 2 trial the companies said on Monday.
Read moreAstraZeneca, KYM sign licensing deal on gastric cancer treatment
23rd Feb 2023 07:39
(Sharecast News) - AstraZeneca and KYM Biosciences have agreed a global exclusive licence agreement for a potential gastric cancer treatment known as CMG901.
Read moreAstraZeneca FY core EPS in line
9th Feb 2023 07:04
(Sharecast News) - Pharma giant AstraZeneca reported full-year earnings in line with expectations and said it expected 2023 core profits to increase by high-single to low-double digits.
Read moreSector movers: Miners and Big Pharma drag
1st Feb 2023 21:33
(Sharecast News) - Miners were again the main drag on the stock market on a mixed day for industrial metals' prices as traders waited on the Federal Reserve's interest rate decision and policy guidance on Wednesday evening.
Read moreAstraZeneca to buy US-based CinCor in $1.8bn deal
9th Jan 2023 07:17
(Sharecast News) - AstraZeneca said on Monday that it has agreed to buy US-based clinical-stage biopharmaceutical company CinCor in a $1.8bn deal.
Read moreAstraZeneca gets new approvals in Japan on three drugs
28th Dec 2022 07:56
(Sharecast News) - AstraZeneca announced on Wednesday that its immunotherapies 'Imfinzi', or durvalumab, and 'Imjudo', or tremelimumab, have been approved in Japan for the treatment of three cancer types - advanced liver, biliary tract and lung.
Read moreAstraZeneca's Imfinzi plus Imjudo recommended for EU approval
19th Dec 2022 08:07
(Sharecast News) - AstraZeneca said on Monday that its Imfinzi (durvalumab) and Imjudo (tremelimumab) combinations have been recommended for marketing authorisation in the European Union for advanced liver and lung cancers.
Read moreAstraZeneca's Forziga recommended for EU use
19th Dec 2022 07:04
(Sharecast News) - AstraZeneca's Forxiga drug has been recommended for approval in the EU for symptomatic chronic heart failure, the pharma company said on Monday.
Read moreFDA gives AstraZeneca extension on cancer drug application
15th Dec 2022 07:49
(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Read moreAstraZeneca hails positive findings in breast cancer drug trial
8th Dec 2022 14:58
(Sharecast News) - AstraZeneca said on Thursday that a phase III trial of its capivasertib drug in combination with Faslodex (fulvestrant) had demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.
Read moreAstraZeneca sells US manufacturing site
30th Nov 2022 07:46
(Sharecast News) - AstraZeneca has agreed to sell a US manufacturing site to National Resilience.
Read more